Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | coagulation factor X | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | = 63 % | Binding to human serum albumin in HPLC assay | ChEMBL. | 17338508 |
Cp (ADMET) | = 3 ml/min.kg | Plasma clearance in Sprague-Dawley rat at 1 mg/kg, iv and 2.5 mg/kg, po | ChEMBL. | 17338508 |
F (ADMET) | = 69 % | Oral bioavailability in Sprague-Dawley rat at 1 mg/kg, iv and 2.5 mg/kg, po | ChEMBL. | 17338508 |
Ki (binding) | = 11 nM | Inhibition of human factor Xa by fluorescence assay | ChEMBL. | 17338508 |
Ki (binding) | = 11 nM | Inhibition of human factor Xa by fluorescence assay | ChEMBL. | 17338508 |
Log D | = 1.49 | Lipophilicity, log D of the compound at pH 7.4 | ChEMBL. | 17338508 |
Ratio IC50 (binding) | > 1300 | Selectivity for factor Xa over kallikrein by fluorogenic assay | ChEMBL. | 17338508 |
Ratio Ki (binding) | = 19 | Selectivity for factor Xa over thrombin by fluorogenic assay | ChEMBL. | 17338508 |
Ratio Ki (binding) | > 700 | Selectivity for factor Xa over plasmin by fluorogenic assay | ChEMBL. | 17338508 |
Ratio Ki (binding) | > 700 | Selectivity for factor Xa over trypsin by fluorogenic assay | ChEMBL. | 17338508 |
Ratio Ki (binding) | > 1000 | Selectivity for factor Xa over activated protein C by fluorogenic assay | ChEMBL. | 17338508 |
Ratio Ki (binding) | > 3500 | Selectivity for factor Xa over tissue factor/factor VIIa by fluorogenic assay | ChEMBL. | 17338508 |
Ratio Ki (binding) | > 3500 | Selectivity for factor Xa over factor XIIa | ChEMBL. | 17338508 |
t1/2 (ADMET) | = 0.57 hr | Half life in Sprague-Dawley rat at 1 mg/kg, iv and 2.5 mg/kg, po | ChEMBL. | 17338508 |
Vss (ADMET) | = 0.17 L/Kg | Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv and 2.5 mg/kg, po | ChEMBL. | 17338508 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.